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Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital, 
University of California, San Francisco, CA, USA
Summary
Background—Xpert MTB/RIF, the most widely used automated nucleic acid amplification test 
for tuberculosis, is available in more than 130 countries. Although diagnostic accuracy is well 
documented, anticipated improvements in patient outcomes have not been clearly identified. We 
performed an individual patient data meta-analysis to examine improvements in patient outcomes 
associated with Xpert MTB/RIF.
Methods—We searched PubMed, Embase, ClinicalTrials.gov, and the Pan African Clinical Trials 
Registry from inception to Feb 1, 2018, for randomised controlled trials (RCTs) comparing the use 
of Xpert MTB/RIF with sputum smear microscopy as tests for tuberculosis diagnosis in adults 
(aged 18 years or older). We excluded studies of patients with extrapulmonary tuberculosis, and 
studies in which mortality was not assessed. We used a two-stage approach for our primary 
analysis and a one-stage approach for the sensitivity analysis. To assess the primary outcome of 
cumulative 6-month all-cause mortality, we first performed logistic regression models (random 
effects for cluster randomised trials, with robust SEs for multicentre studies) for each trial, and 
then pooled the odds ratio (OR) estimates by a fixed-effects (inverse variance) or random-effects 
(Der Simonian Laird) meta-analysis. We adjusted for age and gender, and stratified by HIV status 
and previous tuberculosis-treatment history. The study protocol has been registered with 
PROSPERO, number CRD42014013394.
Findings—Our search identified 387 studies, of which five RCTs were eligible for analysis. 8567 
adult clinic attendees (4490 [63·5%] of 7074 participants for whom data were available were HIV-
positive) were tested for tuberculosis with Xpert MTB/RIF (Xpert group) versus sputum smear 
microscopy (sputum smear group), across five low-income and middle-income countries (South 
Africa, Brazil, Zimbabwe, Zambia, and Tanzania). The primary outcome (reported in three 
studies) occurred in 182 (4·5%) of 4050 patients in the Xpert group and 217 (5·3%) of 4093 
patients in the smear group (pooled adjusted OR 0·88, 95% CI 0·68–1·14 [p=0·34]; for HIV-
positive individuals OR 0·83, 0·65–1·05 [p=0·12]). Kaplan-Meier estimates showed a lower rate of 
death (12·73 per 100 person-years in the Xpert group vs 16·38 per 100 person-years in the sputum 
smear group) for HIV-positive patients (hazard ratio 0·76, 95% CI 0·60–0·97; p=0·03). The risk of 
bias was assessed as reasonable and the statistical heterogeneity across studies was low (I2<20% 
for the primary outcome).
Interpretation—Despite individual patient data analysis from five RCTs, we were unable to 
confidently rule in nor rule out an Xpert MTB/RIF-associated reduction in mortality among 
outpatients tested for tuberculosis. Reduction in mortality among HIV-positive patients in a 
secondary analysis suggests the possibility of population-level impact.
Introduction
Tuberculosis is the leading global cause of death due to an infectious disease. Inadequate 
case detection is a major barrier to current tuberculosis control efforts, contributing to the 
36% of the estimated 10 million cases in 2017 not notified to tuberculosis programmes.1 The 
poor sensitivity of sputum smear microscopy for the detection of acid-fast bacilli coupled 
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with the laboratory infrastructure necessary for Mycobacterium tuberculosis culture provide 
strong impetus for the development of new, programme-relevant tuberculosis diagnostic 
tools.
The introduction of an automated nucleic acid amplification test (NAAT),2 the GeneXpert 
MTB/RIF assay (also known as Xpert MTB/RIF; Cepheid, Sunnyvale, CA, USA) in 
December, 2010, was a groundbreaking advance in tuberculosis diagnostics. Relative to the 
conventional standard (ie, sputum smear microscopy), Xpert MTB/RIF offers improved 
analytic sensitivity and high specificity for individuals not previously treated for 
tuberculosis, and allows for drug susceptibility testing for rifampicin resistance with an on-
demand (ie, random access, without need for batching) quality-controlled system requiring 
only minimal laboratory technician training. However, international scale-up and optimal 
programmatic use of Xpert MTB/RIF has been delayed by high product costs, inadequate 
service and maintenance plans, inability to use the platform within most microscopy centres, 
and lack of attention to dedicated implementation strategies.3–5 Furthermore, despite the 
success of demonstration studies6,7 and early cost-effectiveness models adopting treatment 
benefits derived from observational studies,8,9 evidence for improved morbidity and 
mortality with Xpert MTB/RIF has thus far not been supported by high-quality studies.
As in randomised controlled trials (RCTs) of tuberculosis therapeutics,10 surrogate markers 
for patient-important outcomes for diagnostic-test evaluation—such as test accuracy, 
turnaround time, time to diagnosis, and time to treatment—might not translate onward to 
clinical outcomes and could be subject to substantial hetero-geneity.11 Although therapeutic 
outcomes are similarly of primary interest in diagnostic RCTs,12,13 they have received less 
methodological attention than tuberculosis therapeutic trials.14 Five diagnostic RCTs15–19 
across 41 sites in South Africa, Brazil, Zimbabwe, Zambia, and Tanzania, assessing the 
effect of Xpert among people tested for tuberculosis in routine-care settings have been done. 
Along with consistent increases in the proportion of bacteriologically confirmed cases, the 
possibility of decreased early mortality at 2 months15 and 3 months16 has been raised, 
although estimates have been imprecise. Overall, high rates of empirical tuberculosis 
treatment, a relatively low-risk target population (eg, outpatients), and type 2 error (ie, 
insufficient power) have been most commonly used to explain the absence of effect on 
morbidity or mortality.20
We did a systematic review and an individual patient data (IPD) meta-analysis to examine 
whether use of Xpert MTB/RIF as a replacement for conventional sputum smear microscopy 
improves patient-centred outcomes such as mortality and time to tuberculosis diagnosis and 
treatment. Furthermore, we assessed the possibility of differential effects across prespecified 
patient subgroups, including HIV-positive individuals and those with a previous history of 
tuberculosis treatment.
Methods
Search strategy and selection criteria
For this systematic review and meta-analysis we searched PubMed, Embase, 
ClinicalTrials.gov, and the Pan African Clinical Trials Registry from inception to Feb 1, 
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2018, for RCTs in English; we also contacted experts in the field to identify ongoing and 
completed trials. A search strategy was developed in consultation with an information 
specialist (librarian) who has extensive experience in systematic reviews. Search terms 
included a combination of free text and controlled vocabulary (ie, Medical Subject Headings 
terms): ((tuberculosis AND (mtb/rif OR xpert OR genexpert OR cepheid OR NAAT OR 
NAA test* OR nucleic acid amplification test*)) OR (tuberculosis[mh] AND “nucleic acid 
amplification techniques”[mh])) AND (“randomized controlled trial”[pt] OR random* OR 
“controlled trial”). Additional terms included: “tuberculosis”, “MTB/ RIF”, “Xpert”, 
“GeneXpert”, “Cepheid”, “nucleic acid amplification test”, “NAAT”, and “randomized 
controlled trial”. We excluded studies that were not RCTs; did not use Xpert or sputum 
smear microscopy; included children, patients with extrapulmonary tuberculosis, or patients 
not tested for tuberculosis; did not compare Xpert and sputum smear microscopy; did not 
assess mortality. ARK and JZM did the search and ARK and GLDT extracted data. We used 
IPD for participants aged 18 years and older from randomised trials that, to our knowledge, 
represented the totality of evidence from RCTs evaluating the effect of Xpert MTB/ RIF 
versus sputum smear microscopy on patient outcomes among outpatients tested for 
tuberculosis.
Data analysis
Data were extracted for age, gender, HIV, history of tuberculosis, clinical symptoms, and 
body-mass index (BMI) or weight, where BMI was not available. Data were quality checked 
for each individual trial (all potential duplicates and missing data were assessed with the trial 
contributors) and then assembled to constitute a master data file.
Our primary outcome was cumulative risk (expressed as odds ratio [OR]) of all-cause 
mortality at 6 months following random assignment to groups of clinic attendees tested for 
tuberculosis with Xpert MTB/RIF (Xpert group) versus sputum-smear microscopy (sputum-
smear group). Secondary outcomes were time to death, time to tuberculosis diagnosis (ie, 
time from specimen collection to result available in the laboratory, if bacteriologically 
confirmed), time to tuberculosis treatment (bacteriologically or clinically confirmed), and 3-
month cumulative mortality risk. We calculated the hazard ratio (HR) for time-to-event 
analyses and the OR for the 3-month mortality risk. Separately, among clinic attendees 
investigated for tuberculosis who started receiving tuberculosis treatment, we analysed time 
to death while on treatment. We prespecified stratified analyses for each outcome by HIV 
status and by history of previous tuberculosis treatment. Outcomes for which each study 
contributed data are summarised in the appendix. Risk of bias was assessed using the 
Cochrane Risk of Bias tool by two authors (ARK and JZM).
We did IPD meta-analysis using both one-stage and two-stage approaches.21 We report our 
primary analysis using the two-stage approach, and a sensitivity analysis using the one-stage 
approach. In the two-stage approach, for the binary outcomes (all-cause mortality at 3 
months and 6 months), we fitted a logistic regression model for each study. Robust SEs were 
calculated for any multicentre study and a random-effects (at cluster level) logistic model 
was used for cluster-randomised trials. Pooled estimates were then obtained by fixed-effects 
(inverse variance) or random-effects (Der Simonian Laird) meta-analysis; we reported the 
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results of random-effects meta-analysis when statistical heterogeneity, assessed through a 
formal test of homogeneity and I2, was large (approximately >60%). For time-to-event 
outcomes, we used proportional-hazards Cox models, with robust SEs for multicentre 
studies and a shared frailty (random effect for cluster) for cluster-randomised trials. For 
stepped-wedge trials, we used a random-effects (laboratory-level) Cox model with a fixed 
effect for a covariate set including the timepoints at which Xpert MTB/RIF was introduced. 
All analyses were adjusted for age and gender; estimates of the pooled-intervention effect 
were further adjusted for weight (as a proxy for BMI) and number of tuberculosis symptoms 
(as a categorical variable), when possible. In the one-stage approach, we combined all IPD 
in a single meta-analysis,22 with a hierarchical logistic regression allowing for study and 
cluster (if relevant) random effects for the binary outcomes. Cox models were fitted with 
shared frailties at study level and cluster level (if relevant) for time-to-event outcomes. For 
time-to-tuberculosis diagnosis, a follow-up time of 0·5 days was assumed for patients 
diagnosed on the same day as sputum collection. Only specimens taken at enrolment were 
used to define the time-to-tuberculosis diagnosis outcome. Data management and statistical 
analyses were done with Stata 14.
We prespecified our analytical plan in accordance with international recommendations23 and 
registered the study protocol with PROSPERO (CRD42014013394).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
Results
Our database search identified 387 potentially eligible studies. After the exclusion of 14 
duplicates, of 353 studies after title and abstract screening, and of 15 studies after whole-text 
screening, we found five eligible RCTs comparing the use of Xpert MTB/RIF versus sputum 
smear microscopy for the diagnosis of tuberculosis (figure 1).15–19
All trials included participants aged 18 years or older. The XTEND study18 was a cluster-
randomised trial randomly allocating 20 laboratories in medium-burden districts in four 
South African provinces (n=4656 patients) to assess 6-month mortality among clinic 
attendees being tested for tuberculosis. Using weeks randomly allocated to Xpert or sputum-
smear groups, Cox and colleagues17 analysed 1985 patients at a single primary health-care 
clinic in Khayelitsha, Cape Town, South Africa, and assessed the proportion of patients with 
bacteriologically confirmed tuberculosis who had not started receiving appropriate 
tuberculosis treatment within 2 months after enrolment. Mupfumi and colleagues16 
randomly assigned 424 HIV-positive patients initiating antiretroviral therapy at a single 
centre in Harare, Zimbabwe, to be tested for tuberculosis with either Xpert MTB/RIF or 
sputum smear microscopy, and examined a composite endpoint of 3-month mortality and 
antiretroviral therapy-associated tuberculosis (ie, unmasking of subclinical tuberculosis 
disease). The TB-NEAT study15 randomly assigned to either Xpert or sputum-smear groups 
1502 patients attending primary care clinics in South Africa, Tanzania, Zambia, and 
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Zimbabwe who had at least one tuberculosis symptom (two if HIV-negative) and were able 
to expectorate two sputum specimens; the primary outcome was tuberculosis-related 
morbidity at 2 months and 6 months. Durovni and colleagues19 did a stepped-wedge cluster-
randomised trial (CRT) in Rio de Janeiro and Manaus, Brazil, randomising the sequence of 
Xpert MTB/RIF introduction in 14 laboratories (24 227 patients) and assessing the 
notification proportion of laboratory-confirmed pulmonary tuberculosis. A second 
publication24 from the same research group reported mortality outcomes among patients 
who were initiated on tuberculosis treatment in the primary trial; these data contributed to 
the current analysis.
Our patient-level pooled analysis included data from 8567 adult outpatients tested for 
tuberculosis. Participant characteristics, stratified by trial and according to initial 
randomisation (ie, intention to treat), are shown in table 1. Overall HIV-positivity in these 
trials was 63·5% (4490 of the 7074 participants tested for HIV; ranging from 59%17 to 
100%16); overall, 54·5% (4665 of 8567) of participants were women and the median age 
was 37 years (IQR 29–47 years). Except for the inability to blind the intervention (for all 
trials), and lack of allocation concealment (for two trials),17,19 risk of bias was assessed to 
be reasonable and the statistical heterogeneity across studies was generally low (I2 <20% for 
the mortality outcomes; appendix). For the primary outcome of 6-month mortality risk 
among outpatients tested for tuberculosis, 399 (4·9%) primary endpoints among 8142 
individuals (three studies; figure 1)15,17,18 contributed to the analysis. Overall all-cause 6-
month mortality occurred in 182 (4·5%) of 4050 patients in the Xpert group and 217 (5·3%) 
of 4093 patients in the sputum-smear group (pooled OR 0·88, 95% CI 0·68–1·14; p=0·34); 
stratified analysis showed a pooled OR of 0·83 (0·65–1·05; p=0·12) for HIV-positive 
individuals and 0·83 (0·46–1·5; p=0·55) for HIV-negative individuals. Analysis of 3-month 
mortality (four studies)15–18 and stratification by history of previous tuberculosis gave 
results similar to the overall estimate (table 2).
Time to death among clinic attendees investigated for tuberculosis included 425 (5·0%) 
events among 8561 individuals (four studies)15–18 over 3983 person-years of follow-up. 
With time-to-event analysis, there were 9·69 deaths per 100 person-years in the Xpert group 
and 11·63 deaths per 100 person-years in the smear microscopy group (HR 0·83, 95% CI 
0·65–1·06; p=0·13; figure 2). These results were similar in sensitivity analyses adjusting for 
age, gender, weight, and tuberculosis symptoms (6568 individuals from three studies;15,16,18 
appendix). Among HIV-positive individuals, all-cause death in the Xpert group (12·73 per 
100 person-years) was lower than in the sputum-smear group (16·38 per 100 person-years; 
HR 0·76, 0·60–0·97; p=0·03) as per the data from four studies (figure 2).15–18 The 
significance of this finding was maintained after further adjustment for age, gender, weight, 
and tuberculosis symptoms (appendix).
Across all trials, 6468 (19·7%; ranging from 12%18 to 43%15) of 32 794 outpatients 
investigated for tuberculosis ultimately received tuberculosis treatment. Time to tuberculosis 
diagnosis did not differ for 1924 individuals from two studies, with a median of 0·5 days 
(IQR 0·5–10) for each group (pooled HR 1·05, 95% CI 0·93–1·19; p=0·43).15,16 The median 
time to tuberculosis treatment for 8208 individuals from four studies15–18 was 4 days (1–10) 
for the Xpert group versus 5 days (1–15) for the smear group (1·0, 0·75–1·32; p=0·99), 
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although it was shorter for patients in the Xpert group reporting a history of previous 
tuberculosis treatment than for patients in the sputum-smear group (0·73, 95% CI 0·53–0·99; 
p=0·04). In a prespecified subgroup time-to-event analysis of 5797 adults who started 
receiving tuberculosis treatment (all trials),15–19 we found a possible 33% relative decrease 
in the rate of deaths in the Xpert group versus the sputum-smear group (0·67, 0·50–0·90; 
p=0·007). 6-month all-cause mortality was higher among individuals tested for tuberculosis 
but who ultimately did not start receiving treatment than among those initiating tuberculosis 
treatment (4·3% [133 of 3082] in the Xpert group vs 6·7% [182/2715] in the sputum-smear 
group). In this group of individuals, the summary HR for death in the Xpert group versus 
sputum-smear group was 0·89 (0·70–1·14; p=0·34) among all outpatients, and 0·84 (0·67–
1·05; p=0·12) among HIV-positive individuals.
Discussion
In an IPD meta-analysis of 8567 outpatients tested for tuberculosis in five low-income and 
middle-income countries, we were unable to rule in nor rule out a reduction in 6-month all-
cause mortality associated with use of Xpert MTB/RIF as an initial diagnostic test, relative 
to sputum smear microscopy. Our results are consistent with a plausible reduction in 
mortality of up to 32% and up to a 14% increase in mortality, with the best estimate being a 
12% reduction. Xpert MTB/RIF use was not associated with reduced time to tuberculosis 
diagnosis or to commencement of tuberculosis treatment, nor with an increased proportion 
of individuals treated for tuberculosis. We did, however, find modest evidence for decreased 
HIV-specific mortality.
Unlike HIV and malaria—other major global causes of death and morbidity from infectious 
disease—there is no simple and affordable point-of-care test for tuberculosis. In a widely 
cited decision tree model, Keeler and colleagues25 estimated over a decade ago that a new 
rapid tuberculosis diagnostic test with 89% sensitivity and 99% specificity, accessible in 
clinics and hospitals, would prevent some 200 000 tuberculosis deaths annually, or about 
10% of tuberculosis mortality. Investments in Xpert MTB/RIF have accounted for a 
substantial proportion of global tuberculosis diagnostics spending since WHO endorsement 
in December, 2010, with 6·9 million Xpert MTB/RIF cartridges procured in the public sector 
of 130 of the 145 countries eligible for concessional pricing in 2016 alone.26
A clear effect on patient mortality with programmatic use of Xpert MTB/RIF might be 
difficult to detect for several reasons. First, losses within the passive case-finding cascade 
during the prediagnostic, or even pretreatment,27 periods might not be greatly improved by 
Xpert MTB/RIF. Symptomatic or asymptomatic individuals with active tuberculosis who 
never access care or who are not appropriately triaged account for a large proportion of the 
estimated 3·6 million globally undetected cases each year, presumably due to operational 
health-system weaknesses. Although not included in our analytic population, this group 
remains an important focus for tuberculosis programmes and for the implementation of new 
diagnostic strategies in low-income and middle-income countries. Basic, translational, and 
operational research towards a simple, affordable, truly point-of-care test with high 
analytical sensitivity for tuberculosis remains greatly needed. Second, the effect of empirical 
treatment in biasing toward the null in diagnostics studies has been extensively discussed.
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20,28,29
 The decision to initiate treatment in the absence of bacteriological confirmation is 
complex, as it varies by setting,30 patient (eg, highest risk patients might be most likely to 
benefit from early, accurate diagnosis, but also more likely to be empirically treated), time 
since test introduction (eg, enthusiasm after Xpert MTB/RIF training among South African 
National Department of Health staff might have led to baseline imbalances in the XTEND 
trial18 that favoured Xpert MTB/RIF, and empirical treatment has declined substantially over 
time in at least one setting in South Africa, possibly an evolving adaptation to Xpert 
MTB/RIF availability),31 and—probably—trial effects.32 Overall, in the largest analysed 
studies15,18,19 and in a 2017 CRT33 of centralised versus on-site testing, Xpert MTB/RIF did 
not significantly increase the proportion of patients treated for tuberculosis. Finally, 
insufficient power (ie, leading to type 2 error—the risk that a treatment benefit will not be 
shown, even if it exists) is perhaps the most common explanation for failure to reach a 
prespecified primary outcome.34 Although post-hoc power curves might defy interpretation,
36
 to observe a 12% relative mortality reduction with use of Xpert MTB/RIF (eg, a reduction 
from 8% to 7% absolute mortality, consistent with our reported point estimate) with 90% 
power would require 16 064 people per group, not accounting for clustering.
Nevertheless, a prespecified secondary subgroup analysis did suggest a mortality benefit 
among HIV-positive individuals. HIV-associated tuberculosis was one of two priority groups 
(along with individuals investigated for drug-resistant tuberculosis) in the initial 2011 WHO 
Xpert MTB/RIF policy statement,2 and high relative mortality, particularly among those who 
are antiretroviral treatment naive, increases the statistical power to detect an effect in this 
group. Although a secondary outcome, time-to-death analysis included a larger number of 
individuals and a more complete covariate adjustment than 6-month cumulative mortality-
risk analysis (our primary outcome), leading to increased power. Biological plausibility, 
consistency with diagnostic accuracy,37 with modelling data,38 and with the results of a 
CRT39 of tuberculosis screening among adults newly diagnosed with HIV in Malawi, 
reinforce this secondary analysis; therefore, we consider this result as overall modest 
evidence that should be replicated.
In a prespecified subgroup analysis, we found that individuals tested with Xpert MTB/RIF 
and who—regardless of test result—subsequently started tuberculosis treatment had lower 
mortality than those tested with sputum smear microscopy. Interpretation of this finding is 
complex, and is a function of our conception of how these groups are related and of 
perceived direction of bias. Enhanced analytical sensitivity of Xpert MTB/RIF could allow 
the diagnosis of more individuals at an earlier stage in their disease process, or the loss of 
fewer individuals who have a milder disease within the diagnostic cascade, accounting for 
the noted effect (ie, lower mortality), than is possible with sputum smear microscopy. 
Alternatively, unmeasured confounding from a factor unrelated to diagnostic-test 
performance but differentially distributed among those initiating treatment after Xpert 
MTB/RIF versus sputum smear microscopy might account for this apparent association. 
Although arguably the principal mediator of the effect of tuberculosis diagnostic test on 
death and other adverse outcomes, tuberculosis treatment is a post-randomisation process. 
Therefore, the assumption of sequential ignorability (ie, that tuberculosis treatment is 
effectively randomly assigned given baseline covariates and the randomly allocated 
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diagnostic group) cannot be assumed. For this reason, we present these results primarily as 
hypothesis generating.
Our IPD meta-analysis had several limitations. First, complete patient-level data were not 
available for CD4-positive T-lymphocyte counts, tuberculosis symptoms, and BMI for all 
studies, precluding full adjustment for these key covariates, with tuberculosis symptoms and 
BMI being important covariates in the XTEND study.18 Second, we report analysis of our 
data primarily using a two-stage meta-analytic approach, because this was required for 
inclusion of time-phase as a covariate for the stepped-wedge trial included in this meta-
analysis.19 Acknowledging that the one-stage approach better accounts for potential risk of 
ecological bias than the two-stage approach,40 no convincing evidence exists for the 
supremacy of one-stage versus two-stage approaches. Third, our study results might be less 
applicable to Xpert Ultra, which has a lower limit of detection than Xpert MTB/RIF.41 
Fourth, although the XTEND trial18 was analysed according to a cluster-level summary 
approach in its primary publication—as recommended for a small number of clusters42—we 
analysed XTEND herein using random effects; we cannot exclude the possibility that this 
analysis might have led to non-robust intervention-effect estimates for the XTEND study. 
Finally, our analytical population excluded important patient groups who are likely to draw 
particular benefit from Xpert MTB/RIF, including children and those with rifampicin-
resistant tuberculosis.
In conclusion, in this large multicountry IPD meta-analysis, we could neither rule in nor rule 
out a reduction in mortality over a 6-month period among outpatients tested for tuberculosis 
with Xpert MTB/RIF rather than with sputum smear microscopy. Our finding of a potential 
mortality benefit among HIV-positive individuals in our secondary outcome of time to death 
provides justification for trials of novel tuberculosis diagnostics in this or other high-risk 
groups.
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Research in context
Evidence before this study
Relative to acid-fast bacilli sputum smear microscopy, the first Mycobacterium 
tuberculosis-specific automated nucleic acid amplification test—GeneXpert MTB/RIF 
(Xpert MTB/RIF)—has shown improvement in several key surrogate patient outcomes, 
such as analytical sensitivity, test turnaround time, time to treatment initiation, and 
increase in proportion of bacteriologically confirmed cases. However, randomised 
controlled trials among clinic attendees tested for tuberculosis in routine-care settings, the 
endpoints of which have included morbidity and mortality, have produced inconclusive 
results. We hypothesised that pooling these trials in an individual patient data meta-
analysis would provide increased power in determining whether Xpert MTB/RIF does 
confer such downstream benefits.
Added value of this study
By pooling patient-level data from five diagnostic randomised controlled trials (n=8567 
patients) in 41 sites in South Africa, Brazil, Zimbabwe, Zambia, and Tanzania, we found 
that use of Xpert MTB/RIF was not associated with decreased time to either tuberculosis 
diagnosis or commencement of tuberculosis treatment, and did not decisively reduce 
overall 6-month all-cause mortality among outpatients investigated for tuberculosis, 
relative to smear microscopy; our results are consistent with a possible mortality 
reduction of up to 32% and a mortality increase of up to 14%, with the best estimate 
being a 12% reduction. There was modest evidence for a decrease in HIV-specific 
mortality.
Implications of all the available evidence
We were unable to conclusively show Xpert MTB/RIF-associated reduction in mortality 
among clinic attendees tested for tuberculosis relative to sputum smear microscopy. 
There remains uncertainty on this question, in particular around a potential mortality 
benefit among HIV-positive individuals or other high-risk groups. The impact of novel 
diagnostics on overall mortality is likely to remain attenuated in the context of sustained 
health system weaknesses.
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Figure 1: Study selection
RCT=randomised controlled trial. *The primary outcome was limited to three studies15,17,18 
(n=8142), as Mupfumi and colleagues16 limited follow-up to 3 months.
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Figure 2: Kaplan-Meier pooled survival estimates
Shaded areas represent 95% CIs.
Di Tanna et al. Page 15
Lancet Glob Health. Author manuscript; available in PMC 2019 February 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Di Tanna et al. Page 16
Ta
bl
e 
1:
B
as
el
in
e 
pa
rti
ci
pa
nt
 c
ha
ra
ct
er
ist
ic
s
Th
er
o
n
 e
t a
l (2
01
4)1
5
M
up
fu
m
i e
t a
l (2
01
4)1
6
C
ox
 et
 a
l (2
01
4)1
7
C
hu
rc
hy
ar
d 
et
 a
l 
(20
15
)18
D
ur
o
v
n
i e
t a
l (2
01
4)1
9  
a
n
d 
Tr
a
jm
an
 et
 al
 (2
01
5)2
2
Tr
ia
l c
ha
ra
ct
er
ist
ic
s
Ty
pe
 o
f t
ria
l
R
CT
R
CT
CR
T
CR
T
SW
Co
m
pa
ra
tiv
e 
SO
C*
FM
†
FM
FM
FM
ZN
Se
tti
ng
So
ut
h 
A
fri
ca
, Z
im
ba
bw
e,
 
Za
m
bi
a,
 T
an
za
n
ia
H
ar
ar
e 
(Z
im
ba
bw
e)
K
ha
ye
lit
sh
a 
(S
ou
th 
Af
ric
a)
So
ut
h 
A
fri
ca
B
ra
zi
l
A
du
lts
 in
v
es
tig
at
ed
 fo
r 
tu
be
rc
u
lo
sis
A
na
ly
tic
 p
op
ul
at
io
n,
 n
15
02
42
4
19
85
46
56
 
N
A
X
pe
rt 
M
TB
/R
IF
 g
ro
up
, n
 (%
)
 
74
4 
(50
%)
21
4 
(51
%)
 
98
2 
(50
%)
23
24
 (5
0%
)
 
N
A
A
ge
 (S
D)
, y
ea
rs
 
 
39
 (1
2)
 
38
 (1
0)
 
41
 (1
2)
 
38
 (1
3)
 
N
A
Fe
m
al
e,
 n
 (%
)
 
64
3 
(43
%)
23
2 
(55
%)
 
90
0 
(45
%)
28
90
 (6
2%
)
 
N
A
B
M
I (
SD
), k
g/m
2
 
 
21
·9
 (5
·2)
 
N
R
 
 
N
R
 
25
·5
 (6
·9)
 
N
A
W
ei
gh
t (
SD
), k
g
 
 
59
·7
 (1
2·9
)
 
59
·7
 (1
1·7
)
 
 
N
R
 
65
·1
 (1
5·0
)
 
N
A
A
ny
 tu
be
rc
ul
os
is 
sy
m
pt
om
s, 
n 
(%
)
14
97
 (9
9·9
%)
38
8 
(92
%)
 
 
N
R
43
82
 (9
4%
)
 
N
A
M
ea
n 
nu
m
be
r o
f t
ub
er
cu
lo
sis
 sy
m
pt
om
s (
SD
)
 
 
 
3·
2 
(0·
9)
 
 
2·
3 
(1·
3)
 
 
N
R
 
 
2·
9 
(1·
3)
 
N
A
Pr
ev
al
en
ce
 o
f p
re
v
io
us
 h
ist
or
y 
of
 tu
be
rc
ul
os
is,
 n
 
(%
)
 
36
5 
(24
%)
 
52
 (1
2%
)
 
 
N
R
 
71
8 
(15
%)
 
N
A
H
IV
-
po
sit
iv
e 
in
di
v
id
ua
ls,
 n
/N
 (%
)‡
 
89
5/
14
83
 (6
0%
)
42
4/
42
4 
(10
0%
)
 
96
5/
16
25
 (5
9%
)
22
06
/3
54
2 
(62
%)
 
N
A
Pa
tie
nt
s w
ith
 C
D
4 
≥1
00
 c
el
ls 
pe
r µ
L,
 n
/N
 (%
)‡
 
58
2/
86
1 
(68
%)
27
2/
42
0 
(65
%)
 
 
N
R
 
99
8/
11
30
 (8
8%
)
 
N
A
O
ve
ra
ll 
tri
al
 m
or
ta
lit
y,
 
n
/N
 (%
)
 
12
1/
15
02
 (8
%)
 
28
/3
54
 (8
%)
§
 
71
/1
98
5 
(4%
)
 
20
7/
46
08
 (5
%)
¶
 
N
A
A
du
lts
 in
v
es
tig
at
ed
 fo
r 
tu
be
rc
u
lo
sis
 a
nd
 in
iti
at
ed
 o
n 
tr
ea
tm
en
t
Po
pu
la
tio
n 
of
 a
du
lts
 o
n 
tu
be
rc
ul
os
is 
tre
at
m
en
t 
n
/N
 (%
)
 
64
7/
15
02
 (4
3%
)
10
0/
42
4 
(24
%)
 
54
0/
19
85
 (2
7%
)
 
54
1/
46
56
 (1
2%
)
46
40
/2
4 
22
7 
(19
·2%
)
A
na
ly
tic
 p
op
ul
at
io
n,
 n
||
 
64
7
 
84
 
50
6
 
52
0
40
88
X
pe
rt 
M
TB
/R
IF
 g
ro
up
, n
 (%
)
 
31
5 
(49
%)
 
41
 (4
9%
)
 
27
7 
(55
%)
 
24
0 
(46
%)
22
32
 (5
5%
)
A
ge
 (S
D)
, y
ea
rs
 
 
38
·9
 (1
1·8
)
 
36
·9
 (9
·7)
 
37
·7
 (1
0·1
)
 
37
·9
 (1
1·8
)
 
*
*
Fe
m
al
e,
 n
 (%
)
 
28
9 
(45
%)
 
32
 (3
8%
)
 
30
6 
(61
%)
 
22
5 
(43
%)
14
44
 (3
5%
)
B
M
I (
SD
), k
g/m
2
 
 
21
·8
 (5
·2)
 
N
R
 
N
R
 
22
·4
 (5
·5)
 
N
R
W
ei
gh
t (
SD
), k
g
 
 
59
·4
 (1
3·0
)
 
56
·1
 (9
·3)
 
N
R
 
58
·6
 (1
1·3
)
 
N
R
Lancet Glob Health. Author manuscript; available in PMC 2019 February 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Di Tanna et al. Page 17
Th
er
o
n
 e
t a
l (2
01
4)1
5
M
up
fu
m
i e
t a
l (2
01
4)1
6
C
ox
 et
 a
l (2
01
4)1
7
C
hu
rc
hy
ar
d 
et
 a
l 
(20
15
)18
D
ur
o
v
n
i e
t a
l (2
01
4)1
9  
a
n
d 
Tr
a
jm
an
 et
 al
 (2
01
5)2
2
A
ny
 tu
be
rc
ul
os
is 
sy
m
pt
om
s, 
n 
(%
)
 
64
5 
(10
0%
)
 
84
 (1
00
%)
 
N
R
 
51
4 
(99
%)
 
N
R
M
ea
n 
nu
m
be
r o
f t
ub
er
cu
lo
sis
 sy
m
pt
om
s (
SD
)
 
 
 
3·
1 
(0·
9)
 
 
3·
1 
(1·
0)
 
N
R
 
 
3·
4 
(1·
0)
 
N
R
In
di
v
id
ua
ls 
w
ith
 p
re
v
io
us
 h
ist
or
y 
of
 tu
be
rc
ul
os
is,
 
n
 (%
)
 
15
5 
(24
%)
 
11
 (1
3%
)
 
N
R
 
89
 (1
7%
)
 
N
R
H
IV
-
po
sit
iv
e 
in
di
v
id
ua
ls,
 n
/N
 (%
)‡
 
40
2/
63
9 
(63
%)
 
84
/8
4 
(10
0%
)
 
29
8/
50
6 
(59
%)
 
26
7/
37
3 
(72
%)
39
9/
20
40
 (2
0%
)
Pa
tie
nt
s w
ith
 C
D
4 
≥1
00
 c
el
ls 
pe
r µ
L,
 n
/N
 (%
)‡
 
26
2/
37
6 
(70
%)
 
43
/8
4 
(51
%)
 
N
R
 
90
/1
16
 (7
8%
)
 
N
R
R
CT
=i
nd
iv
id
ua
lly
 ra
nd
om
ise
d 
co
nt
ro
lle
d 
tri
al
. C
RT
=c
lu
ste
r r
an
do
m
ise
d 
tri
al
. S
W
=s
te
pp
ed
 w
ed
ge
. S
O
C=
sta
nd
ar
d 
of
 c
ar
e.
 F
M
=f
lu
or
es
ce
nt
 m
ic
ro
sc
op
y 
w
ith
 a
ur
am
in
e 
sta
in
in
g.
 Z
N
=d
ire
ct
 li
gh
t m
ic
ro
sc
op
y 
w
ith
 Z
ie
hl
-N
ee
lse
n 
sta
in
in
g.
 N
A
=n
ot
 a
pp
lic
ab
le
. B
M
I=
bo
dy
-m
as
s i
nd
ex
. 
N
R=
no
t r
ep
or
te
d.
*
A
ll 
tri
al
s a
ss
es
se
d 
an
 in
te
rv
en
tio
n 
gr
ou
p 
of
 a
 si
ng
le
 sp
ut
um
 sp
ec
im
en
 a
na
ly
se
d 
w
ith
 X
pe
rt 
M
TB
/R
IF
 (G
en
era
tio
n 3
; C
ep
he
id,
 Su
nn
yv
al
e,
 C
A
, U
SA
) i
n c
los
e c
en
tra
l la
bo
rat
ori
es,
 w
ith
 th
e e
x
ce
pt
io
n 
of
 T
B-
N
EA
T,
15
 
in
 w
hi
ch
 X
pe
rt 
M
TB
/R
IF
 w
as
 d
on
e 
on
 si
te
; a
ll 
tri
al
s a
ss
es
se
d 
a 
SO
C 
gr
ou
p 
of
 a
 si
ng
le
 sp
ut
um
 sp
ec
im
en
 a
na
ly
se
d 
by
 sp
ut
um
 sm
ea
r m
ic
ro
sc
op
y 
as
 n
ot
ed
, e
x
ce
pt
 X
TE
N
D
,1
8  
w
hi
ch
 ex
am
in
ed
 tw
o
 
sp
ut
um
 sp
ec
im
en
s.
† O
ne
 o
f f
iv
e 
sit
es
 (i
e, 
Ifi
si 
D
ay
 C
lin
ic
 in
 M
be
ya
, T
an
za
n
ia
) u
sed
 Z
N 
mi
cro
sco
py
.
‡ H
IV
 st
at
us
 a
nd
 C
D
4 
ce
ll 
co
un
t w
er
e 
un
kn
ow
n
 fo
r a
 c
er
ta
in
 p
ro
po
rti
on
 o
f p
ar
tic
ip
an
ts 
in
 so
m
e 
tri
al
s.
§ D
en
om
in
at
or
 u
se
d 
to
 c
al
cu
la
te
 m
or
ta
lit
y 
w
as
 th
e 
to
ta
l n
um
be
r o
f p
at
ie
nt
s f
or
 w
ho
m
 th
e 
ou
tc
om
e 
co
ul
d 
be
 a
ss
es
se
d 
at
 3
 m
on
th
s f
ro
m
 ra
nd
om
isa
tio
n.
¶ V
ita
l s
ta
tu
s a
t 6
 m
on
th
s f
ro
m
 en
ro
lm
en
t w
as
 u
n
kn
ow
n
 fo
r 4
8 
pa
rti
ci
pa
nt
s.
|| A
na
ly
sis
 p
op
ul
at
io
ns
 m
ig
ht
 d
iff
er
 fr
om
 to
ta
l p
op
ul
at
io
n 
in
iti
at
in
g 
tre
at
m
en
t d
ue
 to
 m
iss
in
g 
da
ta
 o
r l
os
s t
o 
fo
llo
w
-u
p.
*
*
A
ge
 a
na
ly
se
d 
as
 a
 c
at
eg
or
ic
al
 v
ar
ia
bl
e.
Lancet Glob Health. Author manuscript; available in PMC 2019 February 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Di Tanna et al. Page 18
Table 2:
Effect of Xpert MTB/RIF on patient outcomes relative to smear microscopy
Number of adults OR or HR (95% CI) p value I2 p (test of homogeneity)
Adults investigated for tuberculosis
6-month mortality risk15,17,18*
  Overall 8142 0·88 (0·68–1·14)  0·34  0·0%  0·94
  HIV negative 2583 0·83 (0·46–1·5)  0·55  0·0%  0·83
  HIV positive 4066 0·83 (0·65–1·05)  0·12 14·8%  0·31
  No history of tuberculosis 6519 0·95 (0·76–1·19)  0·67  0·0%  0·58
  History of tuberculosis 1623 0·91 (0·51–1·61)  0·74  0·0%  0·39
Time to death
  Overall15–18 8561 0·83 (0·65–1·06)  0·13  0·0%  0·75
  HIV negative15,17,18 2583 0·81 (0·46–1·41)  0·45  0·0%  0·80
  HIV positive15–18 4486† 0·76 (0·60–0·97)  0·03  0·0%  0·47
  No history of tuberculosis15–18 6887 0·87 (0·68–1·1)  0·24  0·0%  0·79
  History of tuberculosis15–18 1674 0·83 (0·49–1·42)  0·50  0·0%  0·46
3-month mortality risk
  Overall15–18 8566 0·91 (0·68–1·20)  0·50  0·0%  0·64
  HIV-negative15,17,18 2583 0·74 (0·38–1·45)  0·38  0·0%  0·94
  HIV-positive15–18 4490 0·86 (0·66–1·13)  0·29  0·0%  0·46
  No history of tuberculosis15–18 6891 1·04 (0·80–1·35)  0·77  0·0%  0·57
  History of tuberculosis15–18 1675 0·79 (0·40–1·58)  0·51  0·0%  0·49
Time to tuberculosis diagnosis15,16‡
  Overall 1924 1·05 (0·93–1·19)  0·43 47·5%  0·17
  HIV positive 1164 0·99 (0·86–1·16) >0·99 25·2%  0·25
Time to tuberculosis treatment
  Overall15–18‡ 8208 1·00 (0·75–1·32)  0·99 85·4% <0·0001
  HIV negative15,17,18‡ 2482 0·88 (0·60–1·30)  0·52 60·2%  0·08
  HIV positive15–18‡ 4251 1·04 (0·76–1·42)  0·80 86·0% <0·0001
  No history of tuberculosis15,16,18‡ 5213 0·9 (0·70–1·17)  0·44 70·0%  0·04
  History of tuberculosis15,16,18 1074 0·73 (0·53–0·99)  0·04  0·0%  0·63
Adults investigated for tuberculosis and initiated on treatment
Time to death
  Overall15–19 5797 0·67 (0·50–0·90)  0·007  0·0%  0·63
  HIV negative15,17–19 2670 0·55 (0·3–1·02)  0·06  0·0%  0·79
  HIV positive15–19 1445 0·85 (0·55–1·31)  0·46 18·0%  0·30
All pooled estimates are adjusted for age and gender and are reported with a two-stage analytic approach with fixed effects, unless heterogeneity 
(I2) was high (ie, I2>60%), in which case random effects are primarily reported. Sensitivity analyses with random effects regardless of 
heterogeneity (I2) estimate, additional covariate adjustment, and a one-stage analytical approach are reported in the appendix. ORs are reported for 
6-month and 3-month mortality risks. HR reported for all time-to-event analyses. OR=odds ratio. HR=hazard ratio.
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*6-month mortality risk was the primary outcome.
†
Five individuals without date of death were excluded.
‡
Random effects used to combine study estimates, as I2 was large.
Lancet Glob Health. Author manuscript; available in PMC 2019 February 07.
